Teva Pharmaceutical Industries Limited
TEVA| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.26B | $16.54B | $15.85B | $14.93B | $15.88B | $16.66B | $16.89B | $18.85B |
| Cost of Revenue | $8.32B | $8.48B | $8.20B | $7.95B | $8.28B | $8.93B | $9.35B | $10.56B |
| Gross Profit | $8.94B | $8.06B | $7.64B | $6.97B | $7.59B | $7.73B | $7.54B | $8.30B |
| Gross Margin | 51.79% | 48.74% | 48.25% | 46.72% | 47.83% | 46.38% | 44.63% | 44.00% |
| Operating Expenses | $6.78B | $8.37B | $7.21B | $9.17B | $5.88B | $11.30B | $7.98B | $9.93B |
| Operating Income | $2.16B | $-303.00M | $433.00M | $-2.20B | $1.72B | $-3.57B | $-443.00M | $-1.64B |
| Operating Margin | 12.50% | -1.83% | 2.73% | -14.72% | 10.81% | -21.44% | -2.62% | -8.68% |
| Net Income | $1.41B | $-1.64B | $-559.00M | $-2.45B | $417.00M | $-3.99B | $-999.00M | $-2.15B |
| Net Margin | 8.16% | -9.91% | -3.53% | -16.39% | 2.63% | -23.95% | -5.92% | -11.40% |
| EPS (Basic) | $1.23 | $-1.45 | $-0.50 | $-2.20 | $0.38 | $-3.64 | $-0.92 | $-2.11 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Show 12 more stories
Insider Trading
View AllCompany
About the company
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.